Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Co. (UK) Ltd. as Sole Book-Running Manager of Viking Therapeutics’ $24.0M IPO
New York, NY – May 6, 2015 – New York City based securities and corporate law firm Sichenzia Ross Friedman Ference LLP (the “Firm”) announced today that the Firm has represented Laidlaw & CO. (UK) Ltd. as the sole book-running manager of the initial public offering (IPO) of Viking Therapeutics, Inc. (NASDAQ: VKTX). The public offering consisted of 3,000,000 shares of the Company’s common stock at a price to the public of $8.00 per share which resulted in aggregate gross proceeds of $24,000,000 before deducting expenses. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The Sichenzia Ross Friedman Ference LLP team was led by Partners Richard A. Friedman and Stephen A. Cohen.
- Sichenzia Ross Ference LLP Represents Lexaria Bioscience Corp. in Close of $11 Million Underwritten Public Offering and NASDAQ Uplisting - January 15, 2021
- Partner Andrew M.J. Bernstein to Present CLE on “Preparing Your Client to Testify Before a Grand Jury” for Lawline - January 11, 2021
- Sichenzia Ross Ference LLP Represents KULR Technology Group, Inc. in $8.0 Million Registered Direct Offering - January 4, 2021